Intervet International, B.V. et al. vs Boehringer Ingelheim Vetmedica, Inc. et al.

Trial Instituted Document

Patent Owner's Preliminary Response

Exhibit 2201 - Allan

Exhibit 2203 - The Pig Site

Exhibit 2202 - Ellis

Exhibit 2205 (part 2 of 3) - Prosecution History of U.S. Patent Appl. No. 14/661,969

Exhibit 2206 (part 3 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2204 - Ramshaw

Exhibit 2205 (part 1 of 3) - Prosecution History of U.S. Patent Appl. No. 14/661,969

Exhibit 2205 (part 3 of 3) - Prosecution History of U.S. Patent Appl. No. 14/661,969

Exhibit 2206 (part 1 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2206 (part 2 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2206 (part 4 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2206 (part 7 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2208 - April 16, 2019 Decision Denying Institution in IPR2018-01788 (Paper 9)

Exhibit 2212 - Fenaux 2003

Exhibit 2217 - Bowersock

Exhibit 2218 - U.S. Patent Appl. No. 11/617,435 (¿¿¿the ¿¿¿435 Application¿¿¿), filed on Dec. 28, 2006

Exhibit 2206 (part 5 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2207 (part 2 of 6) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2209 - April 16, 2019 Decision Denying Institution in IPR2018-01789 (Paper 9)

Exhibit 2210 - Jestin et al., U.S. Patent No. 7,223,407

Exhibit 2211 - Audonnet et al., U.S. Patent No. 6,943,152

Exhibit 2213 - Siebel

Exhibit 2214 - Desrosiers

Exhibit 2215 - Chevez

Exhibit 2206 (part 6 of 7) - Prosecution History of U.S. Patent Appl. No. 13/106,606

Exhibit 2207 (part 1 of 6) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2207 (part 4 of 6) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2207 (part 3b of 5) - Prosecution History of U.S. Patent Application No. 12/136,923

Exhibit 2207 (part 3a of 5) - Prosecution History of US Patent Application No. 12/136,923

Petition for Inter Partes Review of U.S. Patent No. 9,610,345 (Corrected)

Petitioner's Updated Power of Attorney

Petitioner's Updated Mandatory Notices

Notice of Accord Filing Date

Patent Owner's Power of Attorney

Patent Owner's Mandatory Notices Pursuant to 37 C.F.R. 42.8(a)(2)

Complaint in Boehringer Ingelheim Vetmedica, Inc. v. Merck & Co., Inc. and Intervet Inc. a/k/a Merck Animal Health, Case No. 2:18-cv-09534-JMV-JBC (D.N.J. May 21, 2018) (ECF No. 1)

Roof et al., U.S. Patent No. 9,610,345 ("the '345 Patent")

Prosecution History of U.S. Patent No. 9,610,345

Jestin et al., U.S. Patent No. 6,703,023 ("Jestin")

Blanchard et al., Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV-2) proteins, Vaccine 21:4565-4575 (2003) ("Blanchard")

Meng et al., International Publication No. WO 2003/049703 ("Meng")

M. Fenaux, et al., A Chimeric Porcine Circovirus (PCV) with the Immunogenic Capsid Gene of the Pathogenic PCV Type 2 (PCV2) etc., 78 J.Virol. 6297 (2004) ("Fenaux")

Patrick Halbur & Tanja Opriessnig, Update on Porcine Circovirus Type 2 (PCV2)-Associated Diseases, Vet. Diagn. Production Animal Med. ("Halbur")

Bublot et al., U.S. Patent No. 6,497,883 ("Bublot")

Merial, Inc.'s Petition for Inter Partes Review of U.S. Patent No. 8,008,001 Under 35 U.S.C. §§ 311-319 and 37 C.F.R. § 42.1-.80 & 42.100-.123

Declaration of Merrill L. Schaeffer, Ph.D. and enclosures

Fenaux et al., Genetic Characterization of Type 2 Porcine Circovirus (PCV-2) from Pigs with Postweaning Multisystemic Wasting Syndrome 38:2in Different Geographic Regions of North America, etc., 494-2503 (2000) ("Fenaux 2000")

G. Reynaud, S. B¿¿s¿¿me, A. Brun, C. Charreyre, S. Desgouilles, P. Jeannin & S. Rehbein, Safety of a High Dose Administration of an Inactivated Adjuvanted PCV2 Vaccine in Conventional Gilts, 1 PROCEEDINGS OF THE 18TH IPVS CONGRESS 87 (2004) ("Reynaud")

Declaration of Christopher C. L. Chase

D. Mahe, et al., Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes, 81 J. Virol. 1815 (2000) ("Mahe")

M. Fort, A. Olvera, M. Sibila, J. Segales & E. Mateu, Direction of Neutralizing Antibodies in Postweaning Multisystemic Wasting Syndrome (PMWS)-Affected and Non-PMWS-Affected Pigs, Veterinary Microbiology 125, 244-255 (2007) ("Fort")

Porntippa Nawagitgul, Igor Morozov, Steven R. Bolin, Perry A. Harms, Steven D. Sorden & Prem S. Paul, Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein, 81 J.Gen.Virol. 2281 (2000) ("Nawagitgul")

Parisot et al., International Publication No. WO 2005/009462 A2 (Feb. 3, 2005) ("Parisot")

H. Jorio, R. Tran & A. Kamen, Stability of Serum-Free and Purified Baculovirus Stocks Under Various Storage Conditions, Biotechnol Prog. 22, 319-325 (2006) ("Jorio")

G. Sala, et al., Development of Monocolonal Antibodies Based on ELISAs, etc., The 5th International Congress of Veterinary Virology, Veterinary Virology in the New Millennium (2000) ("Sala")

Y. Okuda, et al., Experimental Reproduction of Postweaning Multisystem Wasting Syndrome in Cesaren-deprived, etc., 15 J. Vet. Diag. Invest 107-114 (2003) ("Shibata")

Monique M. van Oers, Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors, 68 Advances Virus Res. 193 (2006) ("van Oers")

Haemophilus Parasuis Bacterin Ingelvac HP-1 Product Label, Boehringer Ingelheim Vetmedica, Inc.

Product News, National Hog Farmer (Dec. 15, 2003).

New Mycoplasma Vaccine Offers Convenience, Effective Protection, High Plains/Midwest Ag Journal (Feb. 14, 2005) http://www.hpj.com/archives/new-mycoplasma-vaccine-offers-convenience-effective-protection/article_aab328d5-1df1-590e-aed8-bc11330a46eb.html.

Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Vaccine and Methods of Using the Same, International Publication No. WO 2005/041890 A2.

John C.S. Harding & Edward G. Clark, Recognizing and diagnosing postweaning multisystemic wasting syndrome (PMWS), 5 Swine Health and Production 201 (1997) ("Harding 1997")

G. M. Allan, et al., Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe, 10 J. Vet. Diagn Invest 3 (1998) ("Allan 1998")

Yuna Kim, Jinhyun Kim, Kyoungsoo Kang & Young S. Lyoo, Characterization of the Recombinant Proteins of Porcine Circovirus Type2 Field Isolate Expressed in the Baculovirus System, 3 J. Vet. Sci. 19 (2002) ("Kim")

Roman M. Pogranichniy, Kyoung-Jin Yoon, Perry A. Harms, Sabrina L. Swenson, Jeffrey J. Zimmerman & Steven D. Sorden, Characterization of immune response of young pigs to porcine circovirus type 2 infection, 13 Viral Immunol. 143 (2000) ("Pogranichnyy")

A. Mankertz., J. Mankertz, K. Wolf & H.J. Buhk, Identification of a protein essential for replication of porcine circovirus, 79 J.Gen.Virol. 381 (1998) ("Mankertz 1998")

P. Rueda, J. Fominaya, J. Langeveld, C. Bruschke, C. Vela & J. Casal, Effect of Different Baculovirus Inactivation Procedures on the Integrity and Immunogenicity of Porcine Parvovirus-like Particles, 19 Vaccine 726-734 (2001) ("Rueda")

A. Dawson, R. E. Harvey, S. J. Thevasagayam, J. Sherington, A. R. Peters, Studies of the Field Efficacy and Safety of a Single-Dose Mycoplasma hyopneumoniae Vaccine for Pigs, The Veterinary Record (Nov. 2, 2002) ("Dawson")

M. Kiupel, G.W. Stevenson, S.K. Mittal, E.G. Clark & D.M. Haines, Circovirus-like Viral Associated Disease in Weaned Pigs in Indiana, 35 Vet. Pathol. 303 (1998) ("Kiupel")

John C.S. Harding, The clinical expression and emergence of porcine circovirus 2, 98 Vet. Microbiol. 131 (2004) ("Harding 2004")

Joaquim Segales, Gordon M. Allan & Mariano Domingo, Porcine circovirus diseases, 6 Animal Health Res. Rev. 119 (2005) ("Segales")

Annette Mankertz & Bernd Hillenbrand, Replication of porcine circovirus type 1 requires two proteins encoded by the viral rep gene, 279 Virology 429 (2001) ("Mankertz 2001")

F. McNeilly, I. McNair, D. P. Mackie, B. M. Meehan, S. Kennedy1 D. Moffett, J. Ellis, S. Krakowka & G. M. Allan, Production, characterisation and applications of monoclonal antibodies to porcine circovirus 2, 146 Arch Virol 909 (2001) ("McNeilly")

Gordon M. Allan & John A. Ellis, Porcine circoviruses: a review, 12 J. Vet. Diagn. Invest. 3 (2000) ("Allan 2000")

Inger Marit Brunborg, et al., Quantitation of porcine circovirus type 2, etc., 122 J. Virological Methods 171 (2004) ("Brunborg")

J. Carr & Garth Veterinary Group, Garth Pig Stockmanship Standards, The Pig Site (Sept. 14, 2018, 2:45 p.m.) http://www.thepigsite.com/stockstds/17/growth-rate/. ("Carr").

R. Moorman, A. Bouma, J. Kramps, C. Terpstra, H. De Smit, Development of a Classical Swine Fever Subunit Marker Vaccine and Companion Diagnostic Test ("Moorman")

M. Kuhn, Comparative Safety Evaluation of a One-dose M.hyopneumoniae bacterin ("RespiSure-One") and a Competitor One-dose M. hyopneumoniae bacterin, Pfizer Animal Health Swine Veterinary Services ("Respisure One")

Chanhee Chae, Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application, 194 Vet. J. 151 (2012) ("Chae").

Ellis et al., U.S. Patent No. 6,517,843 ("Ellis")

P. Offit & R. Jew, Adressing Parents' Concerns: Do Vaccines Contain Harmful Preservatives, Adjuvants, Additives, or Residuals?, 112 Pediatrics 6 (December 2003) ("Offit")

M. Mombarg, Is One More Than Two?, 34 IPVS Health Pig International 3 (March 2004) ("Mombarg")

P.C. Liao, Y.L. Lin, M.H. Jong & W.B. Chung, Efficacy of Foot-and-Mouth Disease Vaccine in Pigs with Single Dose Immunization, 21 Vaccine 1807-1810 (2003) ("Liao")

B. Bosworth, Evaluation of a One-dose Mycoplasma hyopneumoniae Bacterin and a One-dose Erysipelas Rhusiopathie Bacterin, American Association of Swine Veterinarians (2004) ("Pneumonostar Myco _ Panstar Ery")

European Patent No. EP2281829

W.L. Mengeling, T.T. Brown, P.S. Paul & D.E. Gutekunst, Efficacy of an Inactive Virus Vaccine for Prevention of Porcine Parvovirus-Induced Reproductive Failure, 40 Am. J. Vet. Res. 2 (Feb. 1979) ("Mengeling")

J. Srinivasappa, I. Morozou, M. Gill & H. Chu, Efficacy, Safety and Serological Cross-Reactivity of Fort Dodge Animal Health's Swine Influenza Vaccine, American Association of Swine Veterinarians (2003) ("Srinivasappa")

M. Hammer, B. Bosworth, D. Stine, E. Springer, T. Johnson, Evaluation of One-Dose MycoPlasma hyopneumoniae bacterin (PneumoSTAR Myco) at 23 Weeks Post Vaccination, American Association of Swine Veterinarians (2005)

SIV Vaccine, dvm360 (Mar. 1, 2004), http://veterinarynews.dvm360.com/siv-vaccine.

Application No. 10174465.4 Information regarding oral proceedings of 12.09.18

D. Nilubol, et al., The Effect of a Killed Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine Treatment on Virus Shedding in Previously PRRSV Infected Pigs, 102 Veterinary Microbiology 11-18 (2004) ("Nilubol")

S.J. Barteling & J. Vreeswijk, Developments in Foot-and-Mouth Disease Vaccines, 9 Vaccine 75-86 (Feb. 1991) ("Barteling")

H. Bahnemann, Inactivation of Viral Antigens for Vaccine Preparation with Particular Reference to the Application of Binary Ethylenimine, 8 Vaccine 299-303 (1990) ("Bahnemann")

C. Charreyre, S. Beseme, L. Boeuf-Teseschi, M. Bublot & G. Reynaud, Protection Against PCV2 Experimental Challenge in 3 Week-Old Piglets by Maternal Antibodies, Proceedings of the 17th IPVS Congress, Ames, Iowa, USA (2002) ("Charreyre")

Declaration of Dr. Phil Hayes ("Hayes Declaration")

F. Brown, Inactivation of Viruses by Aziridines, 20 Vaccine 322-327 (2002) ("Brown")

P.A. Harms, et al., Experimental Reproduction of Severe Disease in CD/CD Pigs Concurrently Infected with Type 2 Porcine Circovirus and Porcine Reproductive and Respiratory Syndrome Virus, 38 Vet. Pathol. 528-539 (2001) ("Harms")

K. Diehl, et al., A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes, 21 J. Appl. Toxicol. 15-23 (2001) ("Deihl")

M.M. Hulst, D.F. Westra, G. Wensvoort & R.J.M. Moormann, Glycoprotein E1 of Hog Cholera Virus Expressed in Insect Cells Protects Swine from Hog Cholera, 67 J. Virology 9:5435-5442 (Sept. 1993) ("Hulst")

Thomas et al., Effect of PCV2 passive antibody levels on immunization with chimeric PCV1-2 vaccine and challenge with wild-type PCV2, American Association of Swine Veterinarians, 23-26 (2005) ("Thomas")

E. Albina, et al., An Experimental Model for Post-weaning Multisystemic Wasting Syndrome (PMWS) in Growing Piglets, 125 J. Comp. Path. 292-303 (2001).

J. Segales, et al., Quantification of Porcine Circovirus Type 2 (PCV2), et al., 111 Veterinary Microbiology 223-229 (2005).

Declaration of Sylvia D. Hall-Ellis, Ph.D.

Development and Formulation of Veterinary Dosage Forms, 2d Ed. (eds. D. Hardee & D. Baggot), CRC Press (1998) ("Hardee")

M. Fenaux, et al., Cloned Genomic DNA of Type 2 Porcine Circovirus is Infection When Injected Directly into the Liver and Lymph Nodes of Pigs: Characterization of Clinical Disease, etc., 76 J. Virology, 2:541-551 (2002).

A. Olvera, et al., Comparison of Porcine Circovirus Type 2 Load in Serum Quantified by a Real Time PCR, etc., 117 J. Virological Methods 75-80 (2004).

U.S. Patent No. 4,442,035

U.S. Patent No. 4,753,884

U.S. Patent No. 5,789,388

U.S. Patent No. 5,213,795

U.S. Patent No. 9,011,872

L. Truchan, R. Jolie, P. Runnels & D. McGavin, Eighteen Week Duration of Immunity in Pigs Vaccinated at 3 or 8 Weeks of Age with One Dose of a Mycoplasma hyopneumoniae Bacterin, American Association of Swine Practitioners (2000) ("Truchan")

M. Roof, K. Burkhart, and F. Zuckermann, Evaluation of the Immune Response and Efficacy of 1 and 2 dose commercial Mycoplasma hyopneumoniae bacterins, American Association of Swine Veterinarians (2000) ("Roof")

Petitioner's Power of Attorney

Declaration of Darin Madson, D.V.M., Ph.D.

Petition for Inter Partes Review of U.S. Patent No. 9,610,345